Prostate Cancer (PC) is the most common male-specific form of cancer and the third most common form of cancer in the UK. Although cancer treatments are initially effective they become less effective and have significant disadvantages. Against this, there is an urgent need for better treatments. In this lecture, Dr Matthew Lloyd describes a number of different strategies to identify small molecules ('drugs') that can be used to stop the protein AMACR from working and therefore potentially be used to treat prostate cancer.
